

# Antibody Identification & RESOLVIGEN

Ortho Clinical Diagnostics

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

# Agenda

- ✓ Antibody identification
- ✓ The OCD's solution: Resolvigen
- ✓ Resolvigen – History and Overview
- ✓ Resolvigen – How does it work?
- ✓ Resolvigen - Advantages
- ✓ Resolvigen – Applications
- ✓ Resolvigen – Clinical data & Validation
- ✓ Resolvigen – Summary

# Antibody Identification

Ortho Clinical Diagnostics

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

# Antibody Identification in BB/TS

If an irregular antibody to erythrocytes is suspected because of a positive antibody screen or a positive crossmatch or extra positivities in ABO reverse typing or in the case of an unexplained hemolytic transfusion reaction, additional investigations are required in order to detect and identify the possible antibody.

The test method used are the same as those employed for antibody screening. However, it may be necessary to expend the test spectrum, to optimize the test procedure, and, e.g. in case of suspected cold antibodies, to adjust the temperature.

All of this is included in the “Antibody identification” testing.

# Antibody Identification in BB/TS

- The antibody identification is one of the most complex method in IH
- Skill and deep knowledge of the serological behavior of all clinically significant antibodies are required
- Quick availability of immunohematology technical and scientific information is important
- Difficulties in Antibody identification can delay the transfusion to the patient
- The antibody identification is often done manually and customers are required a traceability of the results as well as a process control


# Resolvigen: the OCD's solution

Ortho Clinical Diagnostics

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

# RESOL|VIGEN

## A “Virtual” Immunohematologist Expert



Ortho Clinical Diagnostics

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

# Resolvigen

Resolvigen is an **expert software** developed to assist user in the **interpretation** of antibody identification results and to provide suggestions for **additional tests**

- The software will suggest **antibody specificity** based upon a reaction pattern and information on the antigen expression of the reagent red cells used in the test.


# Resolvigen

- Allow you to create your own Rare Blood Cell Archive :  
An archive with public and private antigens that can be searched by different criteria and used to solve complex identification

# Resolvigen: History and Overview

# Resolvigen – History and Overview

- Resolvigen 2.0 was launched in 2000 – Installed & used in more than 200 transfusion centers
- Has been developed by Technosoft (Milan) in 1999 with OCD Italy collaboration



- Software-CD ROM with USB Key
- Printed user manual

# Resolvigen – History and Overview

Resolvigen is a stand alone software that can run on:

- Windows 95/98/Millennium
- Windows NT/XP
- Linux SuSE 8.08.1

Can be installed on any PC with following characteristics (e.g. Innova PC )

| <b>Hardware description</b> | <b>Minimum</b> | <b>Recommended</b> |
|-----------------------------|----------------|--------------------|
| ➤ Microprocessor            | Celeron 300    | Pentium 400        |
| ➤ memory                    | 64 MB          | 128 MB             |
| ➤ video resolution          | 800x600        | 1024x768           |

*To use Resolvigen , the hardware specific protection key which is delivered with the software has to be installed!*



# Resolvigen: How Does it Work?

Ortho Clinical Diagnostics

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

# Resolvigen - How Does it Work?

*Like an Immunohematologist.....*

- Checks all not reactive RBC sample rows on the Panel
- Excludes all antibodies marked + on any of those rows
- Checks the combination that cover all reacting RBCs
- Tries to exclude the remaining antibodies using additional RBCs

**Edit antigram results**

Antigram description  
Type: Panel A Code: 8RA206

Antigram data


| Cell No. | Rh-hr | Donor Number | Antibody Systems |   |   |   |   |   |                |   |   |   |                 |                 |                 |                 |                 |                 |                 | Test results    |                 |                 |                 |   |   |   |   |   |          |    |    |    |                 |                 |                |     |  |  |  |
|----------|-------|--------------|------------------|---|---|---|---|---|----------------|---|---|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|---|---|---|---|---|----------|----|----|----|-----------------|-----------------|----------------|-----|--|--|--|
|          |       |              | D                | C | E | c | e | f | C <sup>m</sup> | V | K | k | Kp <sup>a</sup> | Kp <sup>b</sup> | Js <sup>a</sup> | Js <sup>b</sup> | Fy <sup>a</sup> | Fy <sup>b</sup> | Jk <sup>a</sup> | Jk <sup>b</sup> | Xg <sup>a</sup> | Le <sup>a</sup> | Le <sup>b</sup> | S | s | M | N | P | Cell No. | RT | 37 | C  | RT <sub>E</sub> | 37 <sub>E</sub> | C <sub>E</sub> | IgG |  |  |  |
| 12       | R1wR1 | 115696       | +                | + | 0 | 0 | + | 0 | +              | 0 | 0 | + | 0               | +               | +               | 0               | +               | +               | 0               | +               | 0               | +               | 0               | + | + | 0 | + | + | 0        | +  | +  | 0  | 12              |                 | 0              |     |  |  |  |
| 13       | R1R1  | 112120       | +                | + | 0 | 0 | + | 0 | 0              | 0 | + | + | 0               | +               | 0               | +               | +               | +               | +               | 0               | +               | 0               | 0               | 0 | + | + | 0 | + | +        | 0  | 13 |    | 4+              |                 |                |     |  |  |  |
| 14       | R2R2  | 112848       | +                | 0 | + | + | 0 | 0 | 0              | 0 | + | 0 | +               | 0               | +               | +               | +               | 0               | +               | 0               | 0               | 0               | 0               | + | + | 0 | + | 0 | +        | 0  | 14 |    | 4+              |                 |                |     |  |  |  |
| 15       | Ror   | 115091       | +                | 0 | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | 0               | +               | +               | +               | 0               | 0               | 0               | + | + | + | + | + | +        | +  | 15 |    | 4+              |                 |                |     |  |  |  |
| 16       | r'r   | 105544       | 0                | + | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | 0               | +               | 0               | +               | 0               | 0               | 0               | + | 0 | + | 0 | + | 0        | +  | 16 |    | 4+              |                 |                |     |  |  |  |
| 17       | r'r   | 302075       | 0                | 0 | + | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | 0               | +               | +               | 0               | +               | 0               | +               | 0 | + | 0 | + | 0 | +        | +  | 17 |    | 0               |                 |                |     |  |  |  |
| 18       | rr    | 112428       | 0                | 0 | 0 | + | + | + | 0              | 0 | + | + | 0               | +               | 0               | +               | 0               | +               | +               | 0               | +               | 0               | +               | + | 0 | + | + | + | +        | 18 |    | 0  |                 |                 |                |     |  |  |  |
| 19       | rr    | 117160       | 0                | 0 | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | +               | +               | 0               | +               | +               | 0               | 0               | 0 | + | + | 0 | + | +        | 19 |    | 4+ |                 |                 |                |     |  |  |  |
| 20       | rr    | 302070       | 0                | 0 | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | 0               | +               | +               | 0               | +               | 0               | 0               | 0 | + | + | + | + | +        | 20 |    | 4+ |                 |                 |                |     |  |  |  |
| 21       | rr    | 111163       | 0                | 0 | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | 0               | +               | +               | 0               | +               | +               | 0               | + | + | + | + | 0 | +        | +  | 21 |    | 4+              |                 |                |     |  |  |  |
| 22       | R1R1  | 114851       | +                | + | 0 | 0 | + | 0 | 0              | 0 | + | 0 | +               | 0               | +               | 0               | +               | 0               | +               | +               | 0               | +               | +               | 0 | + | + | 0 | + | +        | 0  | 22 |    | 4+              |                 |                |     |  |  |  |

Mode of reactivity: 37°C/Antiglobulin, Antiglobulin, Var., Cold

# Resolvigen - How Does it Work?


*Resolvigen3 takes in account also information as:*

- Dose effects
- Effects due to variable antigen expression
- Reactions due to Complement fixation
- Effect of enzymes on antibody reaction
- Behaviour in different phases  
RT, 37°C, Coombs (IgG+C3d),  
Coombs (IgG), Enzymes




# Resolvigen - How Does it Work?

- Identification of antibodies related to antigens on panels
- Gives possible antibody mixes explaining reactions



# Resolvigen - How Does it Work?

- Provides on line reference for antibodies with immunohaematological and clinical data
- Suggests hints for antibody identification with complex mixes or weak antibodies



**Resolvigen help.**

### Anti-Fya: weak.

Very weak anti-Fya antibodies may react in Coombs test with homozygous Fy(a+b-) RBCs only.


If the patient has not been transfused in the last two months, check that target antigen lacks on his own cells.

- 1 Increase [serum/RBCs ratio to 6/1](#) and test against homozygous Fy(a-b+) and Fy(a+b-) RBCs to confirm or deny suspected specificity.
- 2 [Adsorb and elute](#) anti-Fya antibody with Fy(a+b-) RBCs, confirming eluted specificity (procedures [No 10](#) or [No 11](#)) using homozygous Fy(a+) and Fy(a-) RBCs..

See also:  
[Hints for antibody identification](#)  
[Anti-Fya](#)

# Resolvigen - How Does it Work?

- Describes 40 laboratory procedures



**(34) Method for the confirmation of the specificity of a weak, incomplete, warm antibody by adsorption and elution.**

This method can be used to confirm the specificity of a weak incomplete antibody through the use of adsorption and elution techniques.

- 1) Choose RBCs with the maximum expression of the target antigen against which the antibody under investigation is directed. Wash 2 ml of the packed RBCs in saline and completely aspirate the final wash solution.
- 2) Add 4 ml of the serum under investigation and 4 ml of low ionic strength enhancer O.A.E.S. to the RBCs selected in step 1 (unless the RBCs have been pretreated with enzyme to enhance their reactivity).
- 3) Mix and incubate for 30' at 37 °C, centrifuge for 3' at 3000 rpm and transfer the supernatant serum to a second tube.
- 4) Wash the 2 ml of RBCs 4 times in saline.
- 5) Elute the adsorbed antibody using [method No 9](#) with diethyl ether or for antibodies with an anti-Fya, anti-S or anti-s specificity use [method No 11](#) or [No 10](#).
- 6) Label 11 tubes for Panel A and distribute all the eluate available amongst them. Add one drop of the reagent RBCs to the corresponding tube, mix and incubate for 60' at 37 °C. Wash the RBCs 3 times in saline and proceed with antiglobulin testing, check all negative tests microscopically and confirm with Coombs control.

# Resolvigen: Advantages

Ortho Clinical Diagnostics

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

# Resolvigen - Advantages

*Greatly improves:*

- Identification of antibodies mixes that give a **complete covering of panels reactions**
- Reading of **individual scores** and **images** (1+,2+,3+,4+) and accordingly interpretation of results
- Identification of **very weak partially reacting antibodies**

**Edit antigram results**

Antigram description  
Type: Panel A Code: RA326

Antigram data

| Cell No. | Rh-ir       | Donor Number | Rh-Hr |   |   |   |   |   |                |   |   |   |                 |                 |                 | Kell            |                 |                 |                 | Duffy           |                 | Kidd            |                 | Sex lines       |   |   | Lewis |   |                | MNS             |                 |          | P  |    | Lutheran |     | Special antigen typing | Test results |    |     |  |  |  |
|----------|-------------|--------------|-------|---|---|---|---|---|----------------|---|---|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|---|---|-------|---|----------------|-----------------|-----------------|----------|----|----|----------|-----|------------------------|--------------|----|-----|--|--|--|
|          |             |              | D     | C | E | c | e | f | C <sup>m</sup> | V | K | k | kp <sup>a</sup> | kp <sup>b</sup> | Jk <sup>a</sup> | Jk <sup>b</sup> | Fy <sup>a</sup> | Fy <sup>b</sup> | Jk <sup>a</sup> | Jk <sup>b</sup> | Xg <sup>a</sup> | Xg <sup>b</sup> | Le <sup>a</sup> | Le <sup>b</sup> | S | s | M     | N | P <sub>1</sub> | Lu <sup>a</sup> | Lu <sup>b</sup> | Cell No. | RT | 37 | C        | RTc |                        | 37c          | Cc | IgG |  |  |  |
| 1        | R1wR1       | 114130       | +     | + | 0 | 0 | + | 0 | +              | 0 | + | 0 | +               | 0               | +               | 0               | +               | 0               | +               | 0               | +               | 0               | +               | 0               | + | 0 | +     | 0 | +              | 0               | +               | 0        | +  | 0  | +        | 1   |                        |              |    |     |  |  |  |
| 2        | R1R1        | 110269       | +     | + | 0 | 0 | + | 0 | 0              | 0 | + | 0 | +               | 0               | +               | 0               | +               | 0               | +               | 0               | +               | 0               | +               | 0               | + | + | +     | 0 | +              | +               | 0               | +        | +  | 0  | +        | 2   |                        |              |    |     |  |  |  |
| 3        | R2R2        | 112848       | +     | 0 | + | + | 0 | 0 | 0              | 0 | + | 0 | +               | 0               | +               | 0               | +               | 0               | +               | 0               | 0               | 0               | +               | +               | 0 | + | +     | 0 | +              | 0               | +               | 0        | +  | 0  | +        | 3   |                        |              |    |     |  |  |  |
| 4        | Ror         | 114331       | +     | 0 | 0 | + | + | + | 0              | + | 0 | + | +               | +               | 0               | 0               | +               | +               | +               | 0               | 0               | 0               | +               | +               | 0 | + | +     | + | 0              | +               | +               | 0        | +  | 4  |          |     |                        |              |    |     |  |  |  |
| 5        | rY          | 113913       | 0     | + | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | +               | +               | 0               | +               | 0               | +               | +               | 0               | + | + | +     | 0 | 0              | +               | 0               | +        | 5  |    |          |     |                        |              |    |     |  |  |  |
| 6        | rYr         | 111775       | 0     | 0 | + | + | + | 0 | 0              | 0 | + | 0 | +               | 0               | +               | 0               | +               | 0               | +               | 0               | 0               | 0               | +               | +               | 0 | + | +     | + | 0              | +               | +               | 0        | +  | 6  |          |     |                        |              |    |     |  |  |  |
| 7        | rr          | 110157       | 0     | 0 | 0 | + | + | + | 0              | 0 | + | + | 0               | +               | 0               | +               | +               | +               | 0               | +               | 0               | 0               | 0               | +               | + | + | +     | + | +              | 0               | +               | +        | 7  |    |          |     |                        |              |    |     |  |  |  |
| 8        | rr          | 111413       | 0     | 0 | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | 0               | +               | 0               | +               | 0               | 0               | 0               | +               | + | 0 | 0     | + | 0              | +               | 0               | +        | 8  |    |          |     |                        |              |    |     |  |  |  |
| 9        | rr          | 112848       | 0     | 0 | 0 | + | + | + | 0              | 0 | + | 0 | +               | 0               | +               | 0               | +               | +               | +               | 0               | +               | 0               | 0               | 0               | + | + | 0     | 0 | +              | 0               | +               | 0        | +  | 9  |          |     |                        |              |    |     |  |  |  |
| 10       | rr          | 112081       | 0     | 0 | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | +               | +               | 0               | +               | +               | 0               | 0               | 0               | + | + | 0     | 0 | +              | 0               | +               | 0        | +  | 10 |          |     |                        |              |    |     |  |  |  |
| 11       | R1R1        | 114327       | +     | + | 0 | 0 | + | 0 | 0              | 0 | + | 0 | +               | 0               | +               | 0               | +               | +               | +               | 0               | +               | +               | 0               | +               | + | + | +     | 0 | +              | +               | 0               | +        | +  | 11 |          |     |                        |              |    |     |  |  |  |
|          | False cells |              | 0     | 0 | 0 | + | + | + | 0              | 0 | 0 | + | 0               | +               | 0               | +               | +               | +               | 0               | +               | +               | 0               | 0               | 0               | + | + | 0     | 0 | +              | 0               | +               | 0        | +  |    |          |     |                        |              |    |     |  |  |  |



Mode of reactivity: 37°C/Antiglobulin      Antiglobulin      Var.      Cold      Var.

Help      Cancel      OK

# Resolvigen - Advantages

*Allows:*


- Identification of antibodies directed against **public antigens** with a step by step procedure



# Resolvigen - Advantages


*Gives:*

- **rare blood archive** extended to public (very common) and private (very rare) antigens (searched by different criteria)
- **on line documentation including over 200 antibodies** with serological and clinical features (enhance communication between lab and clinicians)



# Resolvigen: Application

# Applications



# Resolvigen: Clinical Data – Validation

# Clinical Data - Validation

*A multi-center study on second level automation*

Aim:

To evaluate the performance of AutoVue Innova/Resolvigen System in difficult conditions

- ★ The Efficacy of the system was evaluated with a comparison among AutoVue Innova/Resolvigen3 antibody interpretation and manual method.
- ★ The Efficiency of the system was evaluated with a comparison between time requested in fully automated process and manual method.

Massimo Ripamonti – Santa Chiara Hospital Trento, Italy  
ISBT 2006

# Participants and Number of Sera tested

- 5 Transfusion Centers:
  - Trento, A. P. S. S. Chiara Hospital
  - Sondrio, A. O. Valtellina Valchiavenna
  - Verona, A. O. Verona
  - Lucca, A. USL 2 Lucca
  - Ragusa, A. O. Civile e M. P. Arezzo Ragusa
- 250 samples
- 50 samples studied by each site
- Ortho BioVue cassettes and RBC used:
  - ▲ IgG, C3D Poly cassette and 0,8% Resolve Panel B and C
  - ▲ Neutral Cassette and 0,8% ficin treated Resolve Panel C

# Antibodies characteristics

- Warm, incomplete (IgG), single, partially reacting in CAT
- Cold with weak incomplete components
- Mixes, from two to four warm, incomplete alloantibodies
  - **With or without cold-complete (IgM) components,**
  - **Some of them partially reacting with Anti-IgG,-C3d cassette**
- Panreactive
  - **Single warm, incomplete,**
  - **Weakly reactive with variable reaction score**
  - **Strong complete, incomplete, haemolytic**

# Antibodies specificities in the samples studied

| single antibodies             |                    | multiple antibodies |                     |
|-------------------------------|--------------------|---------------------|---------------------|
| Anti- Fya (w)                 | Anti- K + Kpa      | Anti- E + S         | Anti- D+c + E       |
| Anti- M(vw)                   | Anti- M(omo)+ D    | Anti- c + E         | Anti- D+e + K       |
| Anti- P1 (variable)           | Anti- Cw + Fya (w) | Anti- Jkb + K       | Anti- D+C + E       |
| Anti- Fyb                     | Anti- D + Fya      | Anti- k + E         | Anti- c + E+s       |
| Anti- Xga (vw)                | Anti- Fya(w) + M   | Anti- D + P1        | Anti- M+K + C       |
|                               | Anti- c + Fya      | Anti- c + E         | Anti- Cw + K + Fya  |
| <b>panreactive antibodies</b> | Anti- D + c        | Anti- e + K         | Anti- D+C + E + K   |
| Anti- H (h)                   | Anti- D + Jka      | Anti- C + P1        | Anti- D+C + E + M   |
| Anti- Vel (vw)                | Anti- s + C        | Anti- Cw + K        | Anti- D+C + E + Fya |
| Anti- Rh17(Hr°)               | Anti- Fyb + E      | Anti- K + s         | Anti- D+C + E + N   |
| Anti- Cha (variable)          | Anti- C + K        | Anti- D + K         |                     |
| Anti- P (h)                   | Anti- Cw + P1      | Anti- Fya + C       |                     |
| Anti- Yta (variable)          | Anti- Fyb + Jkb    | Anti- k + D         |                     |
| Anti- Sc1                     | Anti-N + S         | Anti- E + K         |                     |

w: weak

vw: very weak

h: haemolytic

- 50 different samples x 5 Sites
- Total = 250 samples

# Concordant results among different sites

140 samples, 28 antibodies mixes

|                                | Expected results | Site 1  |     | Site 2  |     | Site 3  |     | Site 4  |     | Site 5  |     | TO  |
|--------------------------------|------------------|---------|-----|---------|-----|---------|-----|---------|-----|---------|-----|-----|
|                                |                  | Inn/Res | Man |     |
| 1                              | Fya              | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 2                              | D + Fya          | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 3                              | c + Fya          | 1       | 1   | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 5   |
| 4                              | D + c            | 1       | 1   | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 5   |
| 5                              | D + Jka          | 1       | 1   | 1       | 1   | 1       | 0   | 1       | 0   | 1       | 1   | 5   |
| 6                              | s + C            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 7                              | Fyb + E          | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 8                              | C + K            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 9                              | P1               | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 10                             | D + C + E + K    | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 11                             | D + C + E + M    | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 12                             | D + C + E + Fya  | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 13                             | Fyb + Jkb        | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 14                             | E + S            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 15                             | c + E            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 16                             | Jkb + K          | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 17                             | k + E            | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 18                             | c + E            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 19                             | Cw + K           | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 1       | 0   | 5   |
| 20                             | D + c + E        | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 21                             | K + s            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 22                             | D + C + E        | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 23                             | D + K            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 24                             | Fyb              | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 25                             | c + E + s        | 1       | 1   | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 5   |
| 26                             | Fya + C          | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 27                             | k + D            | 1       | 1   | 1       | 0   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| 28                             | E + K            | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 1       | 1   | 5   |
| Total n° of concordant samples |                  |         |     |         |     |         |     |         |     |         |     | 140 |

- 140 samples (100%) were identified by AVI/Resolvigen as expected
- 12 of these samples (8,6%) were correctly identified by AVI/Resolvigen while the manual method didn't identify or partially did it.

Better Interpretation

# Discrepant results among different sites

75 samples, 15 antibodies mixes

| Expected results | Site 1    |           | Site 2   |          | Site 3    |           | Site 4   |          | Site 5   |          | TOTAL     |           |
|------------------|-----------|-----------|----------|----------|-----------|-----------|----------|----------|----------|----------|-----------|-----------|
|                  | Inn/Res   | Man       | Inn/Res  | Man      | Inn/Res   | Man       | Inn/Res  | Man      | Inn/Res  | Man      | Inn/Res   | manual    |
| 1 M              | 0         | 0         | 0        | 0        | 1         | 1         | 0        | 0        | 1        | 1        | 2         | 2         |
| 2 K + Kpa        | 1         | 1         | 0        | 0        | 1         | 1         | 0        | 1        | 0        | 1        | 2         | 4         |
| 3 M omo + D      | 1         | 1         | 1        | 1        | 0         | 0         | 0        | 0        | 0        | 0        | 2         | 2         |
| 4 Cw + Fya w     | 1         | 1         | 0        | 0        | 1         | 1         | 0        | 0        | 0        | 1        | 2         | 3         |
| 5 Fya w + M      | 1         | 1         | 1        | 1        | 0         | 0         | 1        | 1        | 1        | 0        | 4         | 3         |
| 6 Cw + K + Fya   | 1         | 0         | 1        | 0        | 1         | 0         | 0        | 0        | 0        | 0        | 3         | 0         |
| 7 D + C + E + N  | 1         | 1         | 1        | 1        | 1         | 1         | 0        | 0        | 1        | 0        | 4         | 3         |
| 8 Cw + P1        | 1         | 1         | 0        | 0        | 0         | 0         | 1*       | 0        | 0        | 1        | 2         | 2         |
| 9 Anti-Xga vw    | 1         | 1         | 1        | 1        | 1         | 1         | 0        | 0        | 1        | 1        | 4         | 4         |
| 10 N + S         | 0         | 0         | 0        | 0        | 0         | 0         | 0        | 0        | 0        | 0        | 0         | 0         |
| 11 D + P1        | 1         | 1         | 1        | 0        | 1         | 1         | 0        | 1        | 0        | 0        | 3         | 2         |
| 12 e + K         | 1         | 1         | 0        | 0        | 1         | 1         | 0        | 0        | 0        | 0        | 2         | 2         |
| 13 C + P1        | 1         | 1         | 1        | 1        | 1         | 1         | 0        | 1        | 1        | 1        | 4         | 5         |
| 14 D + e + K     | 1         | 1         | 0        | 0        | 1         | 1         | 0        | 1        | 1        | 0        | 3         | 3         |
| 15 M +K + C      | 1         | 1         | 1        | 1        | 1         | 1         | 0        | 1        | 1        | 1        | 4         | 5         |
| <b>Total n°</b>  | <b>13</b> | <b>12</b> | <b>8</b> | <b>6</b> | <b>11</b> | <b>10</b> | <b>2</b> | <b>6</b> | <b>7</b> | <b>7</b> | <b>41</b> | <b>40</b> |

Not interpreted as expected by both methods

Better Interpretation

- 41 samples (55%) were identified as expected by AV Innova/Resolvigen
- 26 samples were not interpreted as expected by both methods
  - De-naturated samples
  - Overlapping reactions

# Antibodies vs high incidence antigens

35 samples, 7 antibodies specificities

| Expected antibodies | Site 1   |          | Site 2   |          | Site 3   |          | Site 4   |          | Site 5   |          | TOTAL     |          |
|---------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|-----------|----------|
|                     | Inn/Res  | Man      | Inn/Res   | manual   |
| 1 Anti-Vel          | 1        | 0        | 0        | 0        | 0        | 1        | 1        | 1        | 0        | 0        | 2         | 2        |
| 2 Anti-Rh17(Hro)    | 1        | 0        | 1        | 0        | 1        | 0        | 1        | 0        | 1        | 0        | 5         | 0        |
| 3 Anti-Cha          | 1        | 0        | 0        | 0        | 0        | 0        | 1        | 1        | 0        | 0        | 2         | 1        |
| 4 Anti-P            | 1        | 0        | 1        | 0        | 0        | 0        | 1        | 1        | 1        | 1        | 4         | 2        |
| 5 Anti-Yta          | 1        | 0        | 1        | 0        | 1        | 0        | 1        | 1        | 1        | 0        | 5         | 1        |
| 6 Anti-Sc1          | 1        | 0        | 1        | 0        | 1        | 0        | 1        | 1        | 1        | 1        | 5         | 2        |
| 7 Anti-H            | 1        | 0        | 1        | 0        | 1        | 0        | 1        | 1        | 1        | 0        | 5         | 1        |
| <b>Total N°</b>     | <b>7</b> | <b>0</b> | <b>5</b> | <b>0</b> | <b>4</b> | <b>1</b> | <b>7</b> | <b>6</b> | <b>5</b> | <b>2</b> | <b>28</b> | <b>9</b> |

Better Interpretation

- 28 samples (80%) were identified as expected from AVInnova/Resolvigen
- In 19 samples (54%) AV Innova/Resolvigen identified better than the manual interpretation

# Overall Results

| Sample Reactivity      | Equal Interpretation | Better Interpretation |        | Not interpreted as expected by both methods | TOTAL |
|------------------------|----------------------|-----------------------|--------|---|-------|
|                        |                      | Innova/Res            | Manual |   |       |
| Concordant among sites | 128                  | 12                    | 0      | 0   | 140   |
| Discordant among sites | 33                   | 8                     | 8      | 26  | 75    |
| Panreactive            | 8                    | 20                    | 1      | 6   | 35    |
| <b>Total</b>           | 169                  | <b>40</b>             | 9      | 32  | 250   |

- 209/250 (83,6%) samples were correctly interpreted by the AutoVue Innova/Resolvigen.
- In 40 cases (16%) the AutoVue Innova/Resolvigen gave the expected diagnosis while manual method didn't.
- The help of AutoVue Innova/Resolvigen is incremental with panreactive antibodies. (right diagnosis was obtained 28/35, 80% of the panreactive samples)
- In 9 cases (3,6%) of the samples tested the ability of the expert technician is still very useful and decisive to complete the antibody identification.

# Comparison of Manual and Automated Antibody Identification Processing Times

|   | <b>AutoVue Innova / Resolvigen</b> | <b>Manual BioVue / Interpretation</b> |
|---|------------------------------------|---------------------------------------|
| <b>Mean Hands-on Operator Time*</b>           | <b>5 mins</b>                      | <b>5 mins</b>                         |
| <b>Mean Processing Time (11 cells)</b>        | <b>22 mins 42 sec</b>              | <b>25 mins 12 sec</b>                 |
| <b>Mean Interpretation &amp; Exclusion **</b> | <b>2 mins 9 sec</b>                | <b>8 mins 45 sec</b>                  |
| <b>Mean Total Time</b>                        | <b>29 mins 51 sec</b>              | <b>38 mins 57 sec</b>                 |

\* excluding samples thawing

\*\* excluding panreactive antibodies

# Conclusions

- In simple antibody identification, AutoVue Innova/Resolvigen is useful in providing a fast diagnosis
- Increasing the sample complexity, AutoVue Innova/Resolvigen improves its diagnosis capability and decreases the operator's working time
- In very complex mix and pan-reactive samples Resolvigen is able to give hints and complete the antibody identification even though an immediate diagnosis is not provided

# Resolvigen: Summary

# Resolvigen - Summary

*Automated Antibody identification with AutoVue Innova/Resolvigen provides:*

- Assistance in antibody identification in different samples complexity
- Full traceability and standardization of reaction and results interpretation
- reduced risk of errors
- On line information availability of over 40 procedures and 200 antibodies
- Connection with data management system
- Use of digital signature
- Data exchange between different users (Rare Blood Archive )

|                 |     |   |   |   |                |                 |                 |          |    | Test results |    |    |    |
|-----------------|-----|---|---|---|----------------|-----------------|-----------------|----------|----|--------------|----|----|----|
| vis             | MNS |   |   |   | P              | Lubogen         |                 | Cell No. | RT | 37           | C  | RT | 37 |
| Le <sup>a</sup> | S   | s | M | N | P <sub>1</sub> | Lu <sup>a</sup> | Lu <sup>b</sup> |          |    |              |    |    |    |
| +               | +   | 0 | + | 0 | +              | 0               | +               | 0        |    |              | 0  |    |    |
| +               | 0   | + | + | 0 | +              | 0               | +               | 0        |    |              | 3+ |    |    |
| +               | 0   | + | 0 | + | +              | 0               | +               | 0        |    |              | 0  |    |    |
| +               | 0   | + | + | 0 | +              | 0               | +               | 0        |    |              | 0  |    |    |
| +               | 0   | + | + | + | 0              | 0               | +               | 0        |    |              | 0  |    |    |
| 0               | +   | + | + | + | +              | +s              | 0               | 0        |    |              | 0  |    |    |
| 0               | +   | + | 0 | + | +              | 0               | +               | 0        |    |              | 3+ |    |    |
| +               | 0   | + | + | 0 | +              | +               | 0               | 0        |    |              | 0  |    |    |
| +               | +   | + | + | 0 | +              | +               | +               | +        |    |              | 0  |    |    |
| 0               | +   | 0 | + | + | +              | +s              | 0               | 0        |    |              | 0  |    |    |
| 0               | +   | 0 | + | 0 | 0              | 0               | 0               | 0        |    |              | 0  |    |    |
| r. Cold         |     |   |   |   |                |                 |                 |          |    |              |    |    |    |
| Cancel          |     |   |   |   |                |                 |                 |          |    |              |    |    |    |
| Close           |     |   |   |   |                |                 |                 |          |    |              |    |    |    |



**Thank you**

Ortho Clinical Diagnostics

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES